Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

(Z)-Orantinib

Copy Product Info
😃Good
Catalog No. T9684Cas No. 210644-62-5
Alias (Z)-TSU-68, (Z)-TSU68, (Z)-SU-6668, (Z)-SU6668

(Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.

(Z)-Orantinib

(Z)-Orantinib

Copy Product Info
😃Good
Purity: 98.05%
Catalog No. T9684Alias (Z)-TSU-68, (Z)-TSU68, (Z)-SU-6668, (Z)-SU6668Cas No. 210644-62-5
(Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mg$30In StockIn Stock
10 mg$47-In Stock
25 mgPreferential-In Stock
50 mgPreferential-In Stock
1 mL x 10 mM (in DMSO)$52-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.05%
Appearance:Solid
Color:Orange
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
(Z)-Orantinib ((Z)-SU6668) is an effective, selective, orally active, ATP-competitive inhibitor of Flk-1/KDR, PDGFRβ, and FGFR1 with IC₅₀ values of 2.1, 0.008, and 1.2 μM, respectively. As a potent anti-angiogenic and anti-tumor compound, (Z)-Orantinib ((Z)-SU6668) induces significant regression in established tumors. (Z)-Orantinib serves as a valuable tool for investigating tumor angiogenesis inhibition mechanisms, tumor microenvironment regulation, and targeted anti-cancer strategy development, providing highly reliable experimental support for exploring solid tumor drug mechanisms and drug screening.
Targets&IC50
FLK1/KDR:2.1 μM, FGFR1:1.2 μM, PDGFRβ:0.008 μM
In vitro
(Z)-Orantinib (5-15 minutes) inhibits Flk-1 transphosphorylation, FGFR1 transphosphorylation, and PDGFR autophosphorylation, with Ki values of 2.1 μM, 1.2 μM, and 0.008 μM, respectively [1].
(Z)-Orantinib (0.03-10 μM, 60 minutes) suppresses the increase in KDR tyrosine phosphorylation levels induced by VEGF in HUVECs [1].
(Z)-Orantinib shows dose-dependent inhibitory effects on the mitogenic activity of VEGF- and FGF-induced HUVECs, with IC50 values of 0.34 μM and 9.6 μM, respectively [1].
In vivo
(Z)-Orantinib (4-200 mg/kg, orally administered for 21 days) demonstrated dose-dependent inhibitory effects on the growth of A431 tumors in nude mice [1].
(Z)-Orantinib (75 mg/kg, administered intraperitoneally for 22 days) demonstrated significant inhibition of tumor angiogenesis and vascular formation in mice [1].
(Z)-Orantinib (200 mg/kg, orally administered for 11-27 days) significantly induced regression of established large A431 parazacco spilurus subsp. spilurus xenograft tumors in nude mice [1].
Synonyms(Z)-TSU-68, (Z)-TSU68, (Z)-SU-6668, (Z)-SU6668
Chemical Properties
Molecular Weight310.35
FormulaC18H18N2O3
Cas No.210644-62-5
SmilesC(=C\1/C=2C(NC1=O)=CC=CC2)\C3=C(C)C(CCC(O)=O)=C(C)N3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 40 mg/mL (128.89 mM), Sonication is recommeded.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.2222 mL16.1108 mL32.2217 mL161.1084 mL
5 mM0.6444 mL3.2222 mL6.4443 mL32.2217 mL
10 mM0.3222 mL1.6111 mL3.2222 mL16.1108 mL
20 mM0.1611 mL0.8055 mL1.6111 mL8.0554 mL
50 mM0.0644 mL0.3222 mL0.6444 mL3.2222 mL
100 mM0.0322 mL0.1611 mL0.3222 mL1.6111 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy (Z)-Orantinib | purchase (Z)-Orantinib | (Z)-Orantinib cost | order (Z)-Orantinib | (Z)-Orantinib chemical structure | (Z)-Orantinib in vivo | (Z)-Orantinib in vitro | (Z)-Orantinib formula | (Z)-Orantinib molecular weight